News

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma

Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone

Intravenous Ig Ameliorates Disease in a Murine Model of Anti–Laminin 332 Mucous Membrane Pemphigoid

Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features

Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

The Molecular Tumor Board of the University Cancer Center Schleswig-Holstein has been certified as a center for personalized medicine by the DKG (Deutsche Krebsgesellschaft; German Cancer Society). Our cancer research unit provides bioinformatic services for the molecular tumor board since 2018. Further information: https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2024/Zentrum+f%C3%BCr+Personalisierte+Medizin+_+Onkologie+am+UKSH+zertifiziert-p-210243.html

We passed this years quality assessment for NGS sequencing. Since 2022 we participate in the external quality assessment programme for Next-Generation Sequencing by the BVDH (Berufsverband Deutscher Humangenetiker; association of german human genetics). Further information: https://bvdh-ringversuche.de/downloads/rvinfo/nextgenseq/2023/RV%20NGS%202023%20zusammenfassender%20Abschlussbericht_EN_65815cc73b6563_94970283.pdf